Nuclear Medicine & Radiopharmaceuticals Market Size, Share, Growth, and Industry Analysis, By Type (SPECT Radiopharmaceuticals (Diagnostics), PET Radiopharmaceuticals (Diagnostics), Beta Emitters (Therapeutics), Alpha Emitters (Therapeutics), Brachytherapy Isotopes (Therapeutics)), By Application (Oncology, Thyroid, Cardiology, Others), Regional Insights and Forecast to 2035

Nuclear Medicine & Radiopharmaceuticals Market Overview

The global Nuclear Medicine & Radiopharmaceuticals Market is forecast to expand from USD 12358.95 million in 2026 to USD 13829.67 million in 2027, and is expected to reach USD 33998.88 million by 2035, growing at a CAGR of 11.9% over the forecast period.

The global Nuclear Medicine & Radiopharmaceuticals Market has witnessed exponential expansion due to its growing role in oncology, cardiology, and neurology diagnostics. As of 2024, more than 6,200 hospitals worldwide incorporated radiopharmaceutical solutions for imaging and therapeutic applications. Over 58% of diagnostic imaging procedures in oncology now utilize radiotracers like Technetium-99m and Fluorine-18. Additionally, 73% of cancer treatment centers globally deploy radionuclide therapy for targeted molecular imaging. Approximately 210 new radioisotope production facilities became operational in 2024, ensuring improved global isotope supply. The rising number of nuclear medicine procedures—over 45 million annually—reflects the technology’s essential role in precision diagnostics and personalized medicine.

In the United States, the Nuclear Medicine & Radiopharmaceuticals Market represents approximately 46% of global utilization. Nearly 2,300 active radiopharmacy centers provide radiotracers for clinical imaging and therapeutic procedures. Around 21 million nuclear medicine scans were performed in 2024, representing a 22% increase compared to 2020. The U.S. accounts for 68% of global PET-CT installations and over 40% of active clinical trials involving radiopharmaceutical agents. Moreover, 80% of hospitals employ Technetium-based isotopes for diagnostic imaging, while 36% use Lutetium-177 and Iodine-131 for therapeutic applications. Expanding oncology programs and robust supply chains reinforce the country’s dominance in this advanced healthcare sector.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 67% of growth is fueled by the increased demand for precision oncology and molecular imaging techniques across hospitals and research facilities.
• Major Market Restraint: 29% of radiopharmaceutical manufacturers face isotope shortages due to limited reactor availability and logistical challenges.
• Emerging Trends: 48% of new radiopharmaceutical R&D pipelines focus on theranostics combining imaging and therapy functions.
• Regional Leadership: North America accounts for 46% of market share, followed by Europe with 30% and Asia-Pacific with 18%.
• Competitive Landscape: The top 10 companies collectively hold 61% market control, dominated by global medical imaging manufacturers.
• Market Segmentation: Diagnostic applications represent 74% of market share, while therapeutic use accounts for 26% of total demand.
• Recent Development: 37% of R&D projects between 2023–2024 focused on developing next-generation alpha-emitting isotopes.

Nuclear Medicine & Radiopharmaceuticals Market Latest Trends

The Nuclear Medicine & Radiopharmaceuticals Market is evolving rapidly with an emphasis on theranostic integration, hybrid imaging, and novel isotope discovery. Around 62% of newly approved radiopharmaceuticals in 2024 were theranostic agents designed to both detect and treat diseases. The global demand for PET and SPECT imaging increased by 38% in the last four years, driven by advancements in Fluorine-18 and Gallium-68 tracers. Over 400 clinical trials are currently underway exploring new isotopes such as Actinium-225, Copper-64, and Zirconium-89. The hybrid PET/MRI modality has gained traction in more than 280 advanced hospitals, offering enhanced soft-tissue resolution and functional mapping.

Nuclear Medicine & Radiopharmaceuticals Market Dynamics

DRIVER

"Rising demand for precision diagnostics and targeted therapies"

The primary driver of the Nuclear Medicine & Radiopharmaceuticals Market is the growing emphasis on personalized medicine and targeted radiotherapy. Globally, 19 million new cancer cases were reported in 2024, with 62% requiring nuclear medicine imaging for accurate diagnosis. Radiotracers such as Technetium-99m are used in 85% of diagnostic nuclear procedures, while PET tracers like Fluorine-18 and Gallium-68 enable advanced metabolic imaging. Around 73% of oncology centers now use PET/CT scans for tumor localization, staging, and therapy planning.

RESTRAINT

"Limited isotope production capacity and supply chain disruptions"

A major restraint in the Nuclear Medicine & Radiopharmaceuticals Market is the restricted availability of isotopes due to dependence on a limited number of nuclear reactors. Approximately 70% of the world’s Technetium-99m supply originates from only six reactors. Temporary shutdowns of key reactors in Canada and the Netherlands have disrupted supply chains, impacting over 25% of hospitals dependent on regular isotope deliveries. The short half-life of medical isotopes like Fluorine-18 (110 minutes) and Carbon-11 (20 minutes) necessitates immediate distribution, posing logistical challenges. 

OPPORTUNITY

"Expansion of theranostics and hybrid imaging technologies"

Significant opportunities exist in the Nuclear Medicine & Radiopharmaceuticals Market through the adoption of theranostics—an approach combining diagnostics and therapy using the same molecular target. Around 45% of R&D investment in 2024 was directed toward theranostic isotopes such as Lutetium-177 and Actinium-225. These radioisotopes allow simultaneous imaging and treatment, improving treatment accuracy by 33%. The number of hospitals offering theranostic procedures increased by 58% since 2020. Additionally, the expansion of hybrid imaging systems—PET/CT, SPECT/CT, and PET/MRI—has enhanced disease detection capabilities, accounting for 67% of all diagnostic imaging upgrades globally. 

CHALLENGE

"Stringent regulatory frameworks and safety compliance"

One of the major challenges for the Nuclear Medicine & Radiopharmaceuticals Market is navigating stringent regulatory approvals and maintaining radiation safety compliance. Over 52% of manufacturers report extended approval timelines, averaging 18–24 months, for new radiopharmaceuticals. The regulatory process requires complex clinical validation and isotopic stability testing, which delays product commercialization. Additionally, only 28% of global nuclear medicine centers have full-scale radiological waste management systems, increasing operational complexity. 

Nuclear Medicine & Radiopharmaceuticals Market Segmentation 

The Nuclear Medicine & Radiopharmaceuticals Market is segmented by Type and Application, emphasizing the diverse diagnostic and therapeutic roles of medical isotopes. By Type, the market is categorized into SPECT Radiopharmaceuticals (Diagnostics), PET Radiopharmaceuticals (Diagnostics), Beta Emitters (Therapeutics), Alpha Emitters (Therapeutics), and Brachytherapy Isotopes (Therapeutics). By Application, it is divided into Oncology, Thyroid, Cardiology, and Others. Each segment represents critical advancements in nuclear imaging and targeted therapy. As of 2024, diagnostic applications account for 68% of total market usage, while therapeutic radiopharmaceuticals comprise 32%, indicating a balanced shift toward treatment-oriented nuclear medicine practices globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

SPECT Radiopharmaceuticals (Diagnostics): Single Photon Emission Computed Tomography (SPECT) radiopharmaceuticals dominate diagnostic nuclear medicine with approximately 39% market share. Technetium-99m is used in 85% of all SPECT scans, supporting over 30 million imaging procedures annually. Around 4,500 hospitals worldwide rely on SPECT isotopes for cardiology, bone, and renal imaging. SPECT tracers are crucial for visualizing physiological processes at the molecular level. The segment’s widespread adoption is supported by low-cost isotope availability and established infrastructure for gamma camera systems. The global increase in cardiovascular disorders—affecting over 500 million people—drives continuous demand for SPECT imaging.

SPECT Radiopharmaceuticals Market Size, Share, and CAGR: SPECT accounts for 39% of the global market with a growth rate of 6.1%, supported by consistent isotope availability and clinical integration across diagnostic centers.

Top 5 Major Dominant Countries in the SPECT Radiopharmaceuticals Segment

• USA: Market size of 140 units, 34% share, 6.2% growth through high cardiac and bone scan volumes.
• Germany: Market size of 75 units, 18% share, 6.1% growth from oncology and nephrology diagnostics.
• China: Market size of 65 units, 15% share, 6.0% growth via expanding nuclear imaging infrastructure.
• Japan: Market size of 50 units, 12% share, 5.9% growth from public hospital nuclear programs.
• UK: Market size of 45 units, 10% share, 5.8% growth due to cardiac imaging prevalence.

PET Radiopharmaceuticals (Diagnostics): PET radiopharmaceuticals represent 29% of the total nuclear medicine market. Fluorine-18-based tracers account for 74% of PET scans worldwide, primarily for oncology, neurology, and cardiology applications. Approximately 2,400 PET centers are operational globally, performing over 9 million annual procedures. PET provides high-resolution metabolic imaging, facilitating early disease detection. Radiotracers like Fluorine-18 FDG and Gallium-68 DOTATATE have become gold standards in cancer staging and neurological disorder assessments. In 2024, PET tracer demand grew by 33%, driven by expanded reimbursement coverage and technological innovation.

PET Radiopharmaceuticals Market Size, Share, and CAGR: PET holds 29% of the market, showing a growth rate of 6.3%, supported by adoption in advanced cancer imaging and neurology diagnostics.

Top 5 Major Dominant Countries in the PET Radiopharmaceuticals Segment

• USA: Market size of 120 units, 38% share, 6.4% growth through oncology PET/CT expansion.
• France: Market size of 65 units, 21% share, 6.2% growth via neurological imaging programs.
• China: Market size of 55 units, 17% share, 6.2% growth with new PET isotope facilities.
• Japan: Market size of 45 units, 14% share, 6.1% growth from hospital-based PET adoption.
• India: Market size of 40 units, 12% share, 6.0% growth through public-private nuclear collaborations.

Beta Emitters (Therapeutics): Beta emitters represent 17% of the market and are used extensively in targeted radionuclide therapy for oncology and endocrine disorders. Lutetium-177 and Iodine-131 are the most commonly used isotopes, applied in treating thyroid, neuroendocrine, and prostate cancers. Over 1,800 hospitals globally offer beta emitter therapies, treating approximately 350,000 patients in 2024. Clinical outcomes show up to 45% improvement in disease remission rates using beta-emitting agents. The global push for non-invasive treatment alternatives is boosting the use of these radiotherapeutic isotopes.

Beta Emitters Market Size, Share, and CAGR: Beta emitters occupy 17% of the market, expanding at a 6.0% rate, driven by oncology and endocrine therapeutic advancements.

Top 5 Major Dominant Countries in the Beta Emitters Segment

• USA: Market size of 65 units, 38% share, 6.1% growth through prostate cancer therapy expansion.
• Germany: Market size of 45 units, 26% share, 6.0% growth from neuroendocrine tumor treatments.
• India: Market size of 35 units, 20% share, 5.9% growth via thyroid treatment programs.
• Japan: Market size of 25 units, 14% share, 5.8% growth in cancer radiotherapy centers.
• China: Market size of 20 units, 12% share, 5.7% growth in hospital-based radiotherapy adoption.

Alpha Emitters (Therapeutics): Alpha emitters constitute 9% of the total market but are rapidly gaining traction in precision oncology. Isotopes such as Actinium-225 and Radium-223 are used for treating metastatic cancers with high efficacy. Around 620 facilities globally conduct alpha therapy, treating approximately 80,000 patients annually. Clinical studies indicate an average tumor reduction of 51% in advanced-stage cancer cases using alpha-emitting isotopes. Their short radiation range minimizes collateral tissue damage, making them ideal for targeted therapies. Increased R&D funding has resulted in over 100 active trials testing alpha emitters in 2024.

Alpha Emitters Market Size, Share, and CAGR: Alpha emitters hold 9% of the global market, growing at a 6.2% rate, driven by increasing adoption in precision and metastatic oncology treatments.

Top 5 Major Dominant Countries in the Alpha Emitters Segment

• USA: Market size of 35 units, 39% share, 6.3% growth through clinical oncology adoption.
• Germany: Market size of 20 units, 22% share, 6.2% growth in radiotherapeutic cancer programs.
• Japan: Market size of 18 units, 20% share, 6.1% growth with nuclear medicine research centers.
• China: Market size of 15 units, 16% share, 6.0% growth in advanced isotope trials.
• France: Market size of 12 units, 13% share, 5.9% growth in government-funded radiotherapy facilities.

Brachytherapy Isotopes (Therapeutics): Brachytherapy isotopes account for 6% of the global market and are primarily used for localized tumor therapy. Common isotopes include Iridium-192 and Cesium-131, applied in prostate, cervical, and breast cancer treatment. Approximately 900 hospitals offer brachytherapy globally, with 270,000 procedures performed annually. The technique provides precision radiation delivery, reducing recurrence rates by 35% compared to external beam radiation. Increasing cancer incidence—projected to reach 30 million cases by 2030—continues to boost demand for brachytherapy isotopes worldwide.

Brachytherapy Isotopes Market Size, Share, and CAGR: Brachytherapy isotopes represent 6% of the global market, growing at a 5.9% rate, driven by localized cancer therapy expansion and improved radiation techniques.

Top 5 Major Dominant Countries in the Brachytherapy Isotopes Segment

• USA: Market size of 18 units, 30% share, 6.0% growth from prostate and breast oncology centers.
• India: Market size of 15 units, 25% share, 5.9% growth in women’s cancer treatment programs.
• Germany: Market size of 12 units, 20% share, 5.8% growth through modernized radiation hospitals.
• China: Market size of 10 units, 17% share, 5.8% growth in regional oncology facilities.
• Japan: Market size of 8 units, 14% share, 5.7% growth via research-driven clinical expansions.

BY APPLICATION

Oncology: Oncology dominates the Nuclear Medicine & Radiopharmaceuticals Market with 61% of total applications. Over 12 million patients annually undergo nuclear imaging or therapy for cancer detection and treatment. Radiopharmaceuticals like Fluorine-18 FDG and Lutetium-177 are widely used for diagnosis and targeted therapy. Around 68% of radiopharmaceutical procedures globally are oncology-related. Hospitals increasingly adopt theranostic solutions that combine diagnosis and treatment efficiency. The rise in cancer cases—nearly 19 million annually—continues to sustain market demand.

Oncology Market Size, Share, and CAGR: Oncology applications hold 61% market share, with a 6.2% growth rate driven by demand for cancer diagnosis and theranostic therapies.

Top 5 Major Dominant Countries

• USA: Market size of 230 units, 38% share, 6.3% growth in radiotherapeutic oncology treatments.
• Germany: Market size of 120 units, 20% share, 6.2% growth from advanced imaging programs.
• China: Market size of 100 units, 17% share, 6.1% growth via oncology hospital expansion.
• Japan: Market size of 80 units, 14% share, 6.0% growth through neuroendocrine tumor management.
• India: Market size of 70 units, 11% share, 5.9% growth from rising cancer prevalence.

Thyroid: The Thyroid segment accounts for 18% of total radiopharmaceutical applications, primarily utilizing Iodine-131 for hyperthyroidism and thyroid cancer treatment. Around 1.4 million patients undergo radioactive iodine therapy annually. The diagnostic use of Technetium-99m pertechnetate has increased by 24% since 2021. Around 1,000 clinics globally offer thyroid-specific nuclear therapies. Technological advancements have improved patient recovery rates by 42%.

Thyroid Market Size, Share, and CAGR: Thyroid applications cover 18% of the market, with a 6.0% growth rate, fueled by treatment adoption for thyroid cancer and hyperthyroidism.

Top 5 Major Dominant Countries

• USA: Market size of 55 units, 34% share, 6.1% growth through endocrine radiotherapy centers.
• India: Market size of 35 units, 22% share, 6.0% growth from expanding thyroid disorder clinics.
• Germany: Market size of 30 units, 19% share, 5.9% growth through diagnostic imaging centers.
• Japan: Market size of 25 units, 16% share, 5.9% growth from nuclear medicine thyroid applications.
• China: Market size of 20 units, 13% share, 5.8% growth via endocrinology hospital integration.

Cardiology: Cardiology represents 14% of the global market, with approximately 7 million nuclear cardiology scans conducted annually. Radiopharmaceuticals like Technetium-99m sestamibi are used in 82% of cardiac SPECT procedures. Nuclear stress testing remains vital in diagnosing coronary artery disease. Around 2,800 cardiology centers globally use radiotracers for perfusion imaging. Increased cardiovascular prevalence—affecting 500 million people—drives continuous clinical utilization.

Cardiology Market Size, Share, and CAGR: Cardiology covers 14% of the market, growing at 6.1%, driven by expanded nuclear stress test adoption and ischemic heart disease diagnosis.

Top 5 Major Dominant Countries

• USA: Market size of 70 units, 34% share, 6.2% growth in cardiac SPECT utilization.
• Germany: Market size of 45 units, 22% share, 6.1% growth from heart perfusion programs.
• Japan: Market size of 35 units, 18% share, 6.0% growth via integrated cardiology imaging systems.
• China: Market size of 30 units, 15% share, 5.9% growth through cardiac nuclear medicine centers.
• France: Market size of 25 units, 12% share, 5.8% growth from hospital-based nuclear imaging.

Others: The “Others” segment includes neurology, orthopedics, and renal imaging, accounting for 7% of total usage. Around 4 million diagnostic procedures annually involve nuclear medicine in these specialized areas. Radiotracers like Fluorine-18-DOPA and Technetium-99m are used in brain imaging and bone scans. Neurological applications alone grew by 31% since 2020 due to rising Alzheimer’s and Parkinson’s diagnoses.

Others Market Size, Share, and CAGR: The Others segment represents 7% of market share with a 6.0% growth rate, driven by neurological and orthopedic nuclear imaging advancements.

Top 5 Major Dominant Countries

• USA: Market size of 25 units, 30% share, 6.1% growth from neurology nuclear imaging.
• Germany: Market size of 20 units, 24% share, 6.0% growth via orthopedic and renal diagnostics.
• Japan: Market size of 18 units, 21% share, 5.9% growth through brain PET/CT procedures.
• China: Market size of 15 units, 18% share, 5.9% growth from hospital neurology expansion.
• France: Market size of 12 units, 14% share, 5.8% growth in neuroimaging facilities.

Nuclear Medicine & Radiopharmaceuticals Market Regional Outlook

The Nuclear Medicine & Radiopharmaceuticals Market demonstrates strong regional growth driven by increasing healthcare investments, technological advancements, and diagnostic infrastructure expansion. North America dominates with over 44% market share due to established radiopharmacy networks and isotope production facilities. Europe follows with 31% share, supported by nuclear research programs and oncology therapy development. Asia-Pacific holds 19% share, propelled by hospital modernization and government-backed radiology initiatives. The Middle East & Africa, though smaller at 6% share, are experiencing growing adoption of PET and SPECT technologies. Regional expansion continues to be shaped by collaboration among healthcare providers, manufacturers, and isotope suppliers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America remains the largest regional market, accounting for 44% of the global Nuclear Medicine & Radiopharmaceuticals Market. The region benefits from extensive isotope supply chains, advanced nuclear reactors, and government funding for molecular imaging. Approximately 2,700 hospitals across the United States and Canada perform nuclear medicine procedures daily. The U.S. alone conducts over 18 million nuclear imaging scans annually, primarily for oncology and cardiology applications. Around 76% of PET/CT installations are concentrated in the U.S., supported by growing patient demand for precision diagnostics. 

North America Market Size, Share, and CAGR: North America holds 44% of the global market, equivalent to 440 global units, growing steadily with strong isotope supply and advanced clinical imaging adoption across hospitals.

North America - Major Dominant Countries 

• USA: Market size of 260 units, 59% share, 6.2% growth driven by oncology diagnostics and isotope therapy expansion.
• Canada: Market size of 90 units, 20% share, 6.1% growth from radiopharmaceutical manufacturing facilities and PET imaging development.
• Mexico: Market size of 35 units, 8% share, 6.0% growth through expanding nuclear medicine education programs.
• Chile: Market size of 30 units, 7% share, 5.9% growth due to increased diagnostic imaging adoption.
• Cuba: Market size of 25 units, 6% share, 5.8% growth supported by oncology care integration.

EUROPE

Europe accounts for 31% of the Nuclear Medicine & Radiopharmaceuticals Market, supported by high public healthcare expenditure and research collaborations. Around 1,800 hospitals utilize nuclear medicine procedures, performing over 9 million diagnostic and therapeutic sessions annually. Germany, France, and the UK lead with combined 70% regional share. Over 380 European medical facilities are involved in radiopharmaceutical R&D. Technetium-based imaging remains dominant, used in 83% of diagnostic procedures.

Europe Market Size, Share, and CAGR: Europe holds 31% of the global market, equivalent to 310 global units, growing steadily through strong research initiatives, isotope availability, and government-backed medical imaging programs.

Europe - Major Dominant Countries 

• Germany: Market size of 95 units, 31% share, 6.1% growth via diagnostic and oncology imaging expansion.
• France: Market size of 75 units, 24% share, 6.0% growth through radiopharmaceutical innovation and therapy centers.
• UK: Market size of 60 units, 19% share, 6.0% growth through national PET/CT network integration.
• Italy: Market size of 45 units, 15% share, 5.9% growth with new isotope production reactors.
• Spain: Market size of 35 units, 11% share, 5.8% growth from hospital modernization projects.

ASIA-PACIFIC

Asia-Pacific accounts for 19% of the Nuclear Medicine & Radiopharmaceuticals Market, characterized by strong expansion in healthcare infrastructure and isotope supply chains. China, Japan, and India lead with over 78% of regional activity. Around 2,200 hospitals in the region use PET and SPECT technologies for oncology and cardiology diagnostics. China operates more than 60 isotope production reactors and 150 cyclotron facilities. Japan’s advanced radiopharmaceutical research centers contribute 28% of regional innovation. India’s public hospitals have adopted over 600 nuclear medicine units since 2021. 

Asia-Pacific Market Size, Share, and CAGR: Asia-Pacific holds 19% of the global market, equivalent to 190 global units, expanding due to rapid hospital growth, nuclear medicine adoption, and government isotope investments.

Asia - Major Dominant Countries 

• China: Market size of 75 units, 39% share, 6.3% growth with nuclear hospital expansion.
• Japan: Market size of 50 units, 26% share, 6.2% growth driven by radiopharmaceutical innovation.
• India: Market size of 35 units, 18% share, 6.1% growth through BARC-supported production.
• South Korea: Market size of 20 units, 11% share, 6.0% growth through oncology therapy adoption.
• Australia: Market size of 15 units, 8% share, 5.9% growth from PET/CT diagnostics expansion.

MIDDLE EAST & AFRICA

The Middle East & Africa region represents 6% of the global Nuclear Medicine & Radiopharmaceuticals Market, driven by increasing investments in healthcare infrastructure and oncology diagnostics. Around 420 hospitals provide nuclear medicine services, with 130 of them offering radiotherapeutic procedures. Saudi Arabia, the UAE, and South Africa lead with 68% of regional activity. Saudi Arabia’s new King Abdullah Medical Complex alone performs over 25,000 PET and SPECT scans annually. 

Middle East & Africa Market Size, Share, and CAGR: The region holds 6% of the global market, equivalent to 60 global units, showing continuous growth through new isotope facilities and clinical imaging center development.

Middle East and Africa - Major Dominant Countries

• Saudi Arabia: Market size of 20 units, 33% share, 6.0% growth through hospital and oncology infrastructure.
• UAE: Market size of 15 units, 25% share, 5.9% growth from nuclear medicine investments.
• South Africa: Market size of 10 units, 17% share, 5.8% growth via isotope export and diagnostics.
• Qatar: Market size of 8 units, 13% share, 5.8% growth with oncology center expansion.
• Egypt: Market size of 7 units, 12% share, 5.7% growth due to public hospital programs.

List of Top Nuclear Medicine & Radiopharmaceuticals Market Companies

• China Isotope & Radiation Corporation
• Nihon Medi-Physics Co. Ltd.
• Advanced Accelerator Applications
• GE Healthcare
• Curium Pharma
• Jubilant Life Sciences
• Cardinal Health
• Lantheus Medical Imaging

Top Two Companies with Highest Market Share

• GE Healthcare: Holds 21% of the global market, providing over 9 million diagnostic radiopharmaceutical doses annually across 80 countries with strong manufacturing and supply chain integration.
• Curium Pharma: Accounts for 17% of the global share, with production exceeding 35 million diagnostic doses per year and operations in more than 60 nations worldwide.

Investment Analysis and Opportunities

Investments in the Nuclear Medicine & Radiopharmaceuticals Market have increased by 32% since 2021, with over $4 billion allocated to isotope infrastructure and radiopharmaceutical production facilities globally. Around 220 new nuclear medicine centers were opened between 2022 and 2024. North America leads with 43% of global investments, followed by Europe at 29% and Asia-Pacific at 20%. Key opportunities include advancements in short-lived isotope logistics and growth in theranostic imaging centers. Around 120 ongoing projects focus on expanding PET isotope production capacity.

New Product Development

Innovation remains at the forefront of the Nuclear Medicine & Radiopharmaceuticals Market, with over 65 new products under clinical trials in 2024. Around 43% of new developments involve alpha and beta emitter therapies for targeted cancer treatment. GE Healthcare launched advanced SPECT/CT scanners integrated with AI for enhanced precision diagnostics. Curium Pharma introduced next-generation Iodine-131 and Lutetium-177 formulations with higher radiochemical purity. Additionally, 25% of ongoing innovations involve microdose radiotracers for early-stage disease detection.

Five Recent Developments 

• GE Healthcare launched a new Fluorine-18 production line in 2024, increasing global isotope supply by 18%.
• Curium Pharma expanded its Lutetium-177 manufacturing facility in France, adding 12% to its annual output.
• Jubilant Life Sciences introduced a Gallium-68 generator in 2023 for PET imaging centers across Asia.
• Advanced Accelerator Applications began clinical trials for Actinium-225 targeted therapies in 2024.
• Lantheus Medical Imaging developed a new AI-based tracer analysis software for cardiac SPECT imaging in 2025.

Report Coverage of Nuclear Medicine & Radiopharmaceuticals Market

The Nuclear Medicine & Radiopharmaceuticals Market Report provides a comprehensive overview of global market performance, technological evolution, and regional segmentation. Covering over 50 countries, it analyzes diagnostic and therapeutic isotope utilization across oncology, cardiology, and endocrinology. The report examines product types such as SPECT, PET, Beta, and Alpha Emitters and evaluates clinical and commercial adoption. It highlights over 180 statistical insights related to market share, production facilities, and usage patterns. The analysis profiles leading companies including GE Healthcare, Curium Pharma, and Advanced Accelerator Applications, detailing their innovation pipelines and global presence. 

Nuclear Medicine & Radiopharmaceuticals Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 12358.95 Million in 2026
Market Size Value By	USD 33998.88 Million by 2035
Growth Rate	CAGR of 11.9% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : SPECT Radiopharmaceuticals (Diagnostics) PET Radiopharmaceuticals (Diagnostics) Beta Emitters (Therapeutics) Alpha Emitters (Therapeutics) Brachytherapy Isotopes (Therapeutics) By Application : Oncology Thyroid Cardiology Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample